Where the future of the antibody industry will be decided
Europe’s largest forum for the advancement of antibody discovery and development
A content driven agenda tackling the industries biggest issues
The most impressive mix of expert speakers from global pharmaceutical companies, cutting edge biotechs, research organisations and academia
Focused on bringing partners together
Build new relationships and future partnerships with more hours of dedicated networking than any other antibody event
» register for the 2009 brochure
» register now
Sponsorship opportunities
If you are interested to find out how we can help you move your business forward contact us today about sponsor and exhibition opportunities. You can also download the 5th European Antibody Congress prospectus here.
» download the prospectus
“All is done by the organisers to offer a great programme with hot presentations, case studies and interactive panel sessions. Scientific and business networking opportunities are maximised in a casual atmosphere.”
Dr Alain Beck, Head of Physico-Chemistry, Center of Immunology, Pierre Fabre
Antibodies Industry Survey Results
In February 2009 we asked a select group of industry scientists and business leaders to participate in the survey with the goal of compiling a snapshot of the current antibodies market, and to identify priorities, perspectives, trends and perceived opportunities in the sector.
The results have now been put together and are available to download.
»
download the survey results
“It is exciting to be able to attend the European Antibody Congress which is centered around so many new ideas in the cradle of biologics discovery.”
Dr William Strohl, Executive Director, Department of Biologics Research, Merck & Co.
Key topics include
- Improving Efficacy and Drugability of mAbs
- Fab/Antigen or Fc/Fc-Gamma Receptors Co-Crystalisation Studies to Gain Insights on Structure and mAb Mechanisms of Action
- Antibody Pk and Metabolic Studies
- Antibody Successes and Attrition Rates
- CD20 mAbs in Clinical Development
- IgF-1R mAbs in Clinical Development
- Generation and Identification of mAbs Against New Targets
- Antibody Patents
- mAb Production Scale-Up, Process Transfer and Comparability
- Antibody Humanization, ‘Superhumanization’ and Engineering
- Antibody-Drug Conjugate Development
- Non Classical IgGs: Aglycosylated, Bispecifics and Intrabodies
- Beyond Antibodies: Domain Antibodies and New Scaffolds
